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Markers of Exposure to Carcinogens
by Gerald N. Wogan*
Methods have been developed for the detection ofexposure to carcinogens and other DNA damaging agents
in experimental animals and man through the detection ofcarcinogens or theirmetabolic derivatives in body
fluids, orthrough adducts bound covalently to DNA or hemoglobin. The successful use ofurinary markers
of genotoxic exposures has been reported with respect to nitrosoproline as an indicator ofexposure to N-
nitroso compounds. The same approach has been used to detectAFBI and AFB1-N7-Gua as markers ofex-
posure toaflatoxin B,; of3-methyladenine produced asa result ofexposure to methylating agents; andthy-
mine glycol as an indicator ofexposure to agents causing oxidative damage to DNA. Detection ofadducts
formed between genotoxic agents and hemoglobin has been reported in studies ofpopulations occupation-
ally exposed to ethylene oxide, in which 3-hydroxyhistidine and 3-hydroxyvaline have been measured, and
in smokers, whose hemoglobin has been found to contain levels of4-aminobiphenyl and 3-hydroxyvaline that
were correlated with the frequency ofcigarette smoking.
Detection ofDNAadducts ofgenotoxic agents in the cells andtissues ofexposed individuals has also been
accomplished through the use ofseveral types ofanalytical methods. Immunoassays and physicochemical
methods have been applied to detect adducts formed through the major intermediate in the activation of
benzo(a)pyrene, the 7,8-diol-9,10-epoxide (BPDE). This adduct has been found in the DNA ofperipheral leu-
kocytes ofworkers in foundries, aluminum manufacturing plants, roofers, and coke oven plants, and also
in cigarette smokers. BPDE-DNA adducts have been detected by synchronous scanningfluorescence as well
as by immunoassays conducted in ELISA orUSERIA modes. The successful application ofimmunoassays
to detect DNA adducts ofcis-platinum in leukocytes ofovarian cancer patients receiving chemotherapy and
06-methyl guanine in the blood ofpopulations at high risk for esophageal cancer has also been reported.
The methodof32P-postlabeling forthe detection ofDNAadducts hasconfirmed theirpresence in placentas,
peripheral leukocytes, and oral mucosal cells oftobacco smokers, as well as cokeoven andfoundry workers.
Increased total levels ofadducts were, in general, reflective ofelevated levels ofexposure.
Introduction
Itis an honor to have been invited toparticipate in this
symposium on "Scientific Advances in Environmental
Health," especially since its purpose is to recognize the
many contributions ofDr. Norton Nelson to the develop-
ment ofthe modern fieldofenvironmental health sciences
and to the founding of the Institute of Environmental
Medicine. Through his wisdom, insight, creativity, or-
ganizational genius and inexhaustible energy, he has
played a major role in the initiation and development of
many aspects of environmental health science through-
out the international scientific community. The nature,
scope, and direction ofvirtually every major component
of current environmental health science research have
been influenced directly orindirectlyby Dr. Nelson's ac-
tivities. It is therefore entirely appropriate that this sym-
posium has been organized in his honor, and it is a per-
sonal pleasure for me to have this opportunity to express
my admiration, respect, and appreciation for his many
contributions.
*Department ofApplied Biological Sciences, Massachusetts Institute
ofTechnology, Cambridge, MA 02139.
In certain respects, the current status of the fleld of
markers ofcarcinogen exposure represents a culmination
of efforts to bring together current knowledge about
mechanisms of carcinogenesis and mutagenesis and
highly sophisticated analytical methods to detectmolecu-
lar and cellular events that may be predictive of health
risks. Thisis averytimelyandimportant areaofresearch
endeavor, inasmuch as the process ofrisk assessment is
finding increasing application by regulatory decision-
making bodies in the process offormulating policies in-
tended to minimize health risks resultingfrom exposure
to hazardous substances. The process ofrisk assessment
requirestheuse offactual datato definethe healtheffects
ofexposure ofindividuals or ofpopulations to such sub-
stances. By current definition, theprocess ofrisk assess-
ment includes three elements: hazard identification, dose-
response assessment, and risk characterization. Ex-
posure assessment and epidemiology data are key com-
ponents ofthe dose-response assessment, the objective
ofwhich is to define dose-incidence relationships for ad-
verse health effects (such as cancer) in human popula-
tions. These components, togetherwith animalbioassay
data, appropriate extrapolations ofinformation concern-
ing dose-effects in animals, and interspecies differencesG. N. WOGAN
in response, effectively determine the quantitative fea-
tures ofthe risk estimation and are therefore ofcritical
importance.
Epidemiologic studies designed to evaluate the health
significance of environmental chemicals, including car-
cinogens, are seriously compromised by the lackofquan-
titative exposure datafor individuals in exposed popula-
tions. Monitoring data on levels of compounds in
environmental media often represent the only informa-
tion available, and average population exposure is there-
fore the only quantitative parameter that can be calcu-
lated. Biological monitoring, i.e., measurements that can
be made on cells, tissues, or body fluids ofexposed peo-
ple, has the objective ofdefining "dose" (internal orbio-
logically effective) on an individual basis. Information
gained from such measurements has the potential for
identifying potentially hazardous exposures before ad-
verse health effects appear and also for establishing ex-
posure limits for minimizing the likelihood ofsignificant
health risks. Because measurements are made on in-
dividuals, theyprovide anindication notonlyofexposure
to agiven substance, but also ofthe amountabsorbedand
metabolically transformed to activated derivatives, viz.,
the fraction bound tofunctionally important cellular sites.
Biological monitoring data provide information com-
plementary to that derivedfrom analysis ofenvironmen-
tal media, andbecause they canbe interpreted in the con-
text of known mechanisms of action, are more directly
relevant to assessment ofhealth risks. Exposure assess-
ment strategiesbased onbiologicalmonitoringcanthere-
fore be designed to take into account exposures through
multiple routes and integrate the consequences ofinter-
mittent aswell as continous exposures. They canalsopro-
vide evidence oftotal risk from multiple sources and to
multiple agents.
Certain attributes will be indispensable for a method-
ology to be adequate to provide accurate, quantitative
measurements ofexposure to environmental carcinogens
and at the same time to fulfill the objective ofproviding
early indication of long-term risk of cancer. Important
amongthese attributes are the following: a) The analyt-
ical methods mustbe adequate to detect and quantify ex-
posure to carcinogens/mutagens at ambient levels in the
environment; b)they must be applicable to cells orbody
fluids that are readily accessible; c) measured values
shouldbe quantitatively related to exposure levels over
awide range; and d)they should integrate consequences
of intermittent or continuous exposures to multiple
agents. All ofthese attributes are applicable to accurate
dosimetry ofexposure alone. In order to be applicable in
addition to the assessment of health risk, the methods
should alsobe capable ofdetectingearlybiological effects
predictive oflong-term adverse health risks (i.e., cancer).
The methods used inproducing the information summa-
rized in the following discussion are applicable to detec-
tion ofexposure; at present, none ofthese canbe consid-
ered adequately validated to provide direct evidence of
cancerrisk. Strategies for use ofexposure information in
the prospective assessment ofgenetic riskrepresent im-
portant future challenges, and their development and
validationwill require agreat deal ofadditional research.
The subjects of biological monitoring and its applica-
tions in the field that has come to be known as molecu-
larepidemiology havebeenthe subjects ofseveralrecent
comprehensive reviews. This discussion will emphasize
detection methodology and will summarize currently
available inforrnation on carcinogen exposure. A broader
perspective onthefieldcanbefoundin severalmore com-
prehensive reviews (1-8).
Indicators of Genotoxic Exposures
Methods for detecting exposures to DNA damaging
agents fall into two categorical types: measurements of
levels of genotoxic chemicals, their metabolites and/or
derivatives in cells, tissues, body fluids or excreta; and
measurements ofbiological responses such as cytogenetic
changes in exposed individuals. This discussion will em-
phasize recent developments in the former category, al-
though important advances are beingmade in the devel-
opment and application of biological indicators of
genotoxic exposures aswell. These include mutation mar-
kers based on altered phenotype [e.g., hypoxanthine
phosphoribosyl transferase (HPRT) deficiency in
peripheral leukocytes]; alteredgeneproduct(e.g., mutant
glycophorin in erythrocyte membranes); gene inactiva-
tion (loss ofspecific mRNA); or altered DNA sequences
(restriction fragment length polymorphism, or transloca-
tions involving oncogene sequences). Chromosomal mar-
kers that have been useful in detecting damage from
genotoxic agents include structural aberrations, sister
chromatid exchanges, and aneuploidy. The presence of
micronuclei in circulating erythroid cells provides an ad-
ditional index ofgenotoxicity.
Chemical dosimetersfor severaltypes ofgenotoxic ex-
posures are also available for detection ofcarcinogen ex-
posures. Major approaches depend on chemical or im-
munological analytical methods for the detection of
carcinogens or their metabolic derivatives in blood or
urine. Mutation assays inbacteria have also beenused to
detectthe presence ofmutagens inurineinrelation to en-
vironmental exposures. A third avenue ofinvestigation
has been the detection of covalent adducts formed be-
tween carcinogens/mutagens andcellularmacromolecules
such as proteins (e.g., hemoglobin), or cellular DNA, or
excreted in urine.
Detection of Carcinogen Exposure
in Man
Development ofthese detectionmethodologieshasper-
mitted studies designed to evaluate their adequacy for
detecting exposure to carcinogens in man. Results of
several such studies have beenpublished, andTables 1-5
summarize currently available dataextractedfrompub-
lished reports dealingwith various aspects ofbiomonitor-
ing ofexposure ofhumans to genotoxic agents ofa vari-
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ety of types and sources. These tables contain
representative data, particular emphasis having been
placed on those aspectsthat arepertinent tomethodvali-
dation.
Urinary Excretion of Markers
Table 1 summarizes findings from a series ofstudies in
which excretion ofurinary markers ofcarcinogen inter-
Table 1. Urinary excretion of markers of genotoxic exposures.
Urinary marker Exposure analysis Exposure levela Excretion rate
Nitrosamino acids Unknown High risk area (44) 21.2 Mg/day
Low risk area (40) 5.6 ,ug/day
Nitrosoproline Cigarette smoke Smokers (13) 5.9I*g/day
Nonsmokers (13) 3.6 pg/day
Nitrosoproline Unexposed Nonsmokers (24) 3.3 Mg/day
AFB1 Diet Exposed subjects (20) 0.1-10 1.g/day, AFBI equivalents
AFB,-N7-GuA
AFB1-N7-GuA Diet Low/high risk areas (983) 12% positive
3-Me-adenine None Unexposed subjects (9) 4.5-16.1 ,g/day
Thymine glycol None Unexposed subjects (9) 0.39 nmole/kg/day
Thymidine glycol 0.10 nmole/kg/day
aNumbers in parentheses are numbers of subjects.
Table 2. Hemoglobin adducts as markers of genotoxic exposure.
Compound analyzed Exposure source Exposure levela Adduct level
N-3-(2-Hydroxyethyl)histidine Ethylene oxide Exposed (5) 0.5-13.5 nmole/gHb
(occupational) Control (2) 0.05 nmole/gHb
N-3-(2-Hydroxyethyl)histidine Ethylene oxide Exposed (32) 2.08 nmole/gHb
(occupational) 1.59 nmole/gHb
N-3-(2-Hydroxyethyl)histidine Ethylene oxide Exposed (7) 0.68-8.0 nmole/gHb
(occupational) Control (3) 0.53-1.6 nmole/gHb
Hydroxyethylvaline Ethylene oxide Exposed (7) 0.02-7.7 nmole/gHb
(occupational) Control (3) 0.03-0.93 nmole/gHb
Hydroxyethylvaline Cigarette smoke Smokers (11) 389 pmole/gHb
Nonsmokers (14) 58 pmole/gHb
4-Aminobiphenyl Cigarette smoke Smokers (15) 154 pg/gHb
Nonsmokers (26) 28 pg/gHb
aNumbers in parentheses are numbers of subjects.
Table 3. Detection of BPDE adducts in DNA by immunoassay or chemical analysis.
No. of subjects
in which adducts
Type of assaya DNA source Exposure source were found Adduct level
ELISA Lung Tumor/nontumor 5/27 0.14-0.18 fmole/*g DNA
ELISA WBC Roofers 7/28 2-120 fmole/50 Mg DNA
WBC Foundry workers 7/20
WBC Controls (smokers) 2/9 37-47 fmole/50 ,ug DNA
SSFS WBC Aluminum workers 1/30 Positive
WBC Controls 0/10
USERIA WBC Coke oven workers 18/27 0.4-34.3 fmole/4g DNA
SSFS WBC Coke oven workers 31/41 Positive
11/41 Positive for serum antibodies
USERIA WBC Coke oven workers 13/38 0.1-13.7 fmole/pg DNA
SSFS WBC Coke oven workers 4/38 0.38-2.2 fmole/lAg DNA
ELISA WBC Foundry workers 22 1.2 fmole/t4g DNA
(high, medium, low exposure) 0.53 fmole/4g DNA
0.32 fmole/Ag DNA
Controls 10 0.06fmole/4g DNA
aELISA, enzyme-linked immunosorbent assay; SSFS, synchronous scanningfluorescence spectrophotometry; USERIA, ultrasensitive enzyme radio-
immunoassay.
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Table 4. Detection of06-methyl guanine and cis-platinum DNA adducts by immunoassay.
Compound analyzed Source of DNA Adduct level
06-MeG Esophagus/stomach tumor/nontumor (27/37)a 25-160 fmole/,g DNA
European controls (5/12) 25-45 fmole/,ug DNA
cis-DDP-DNA WBC 5.6 fmole pGpG/Ig DNA
Infused patient 1.9 fmole pApG/Mg DNA
1.1 fmole (GMP)2/,g DNA
0.06 fmole GMP/JAg DNA
cis-DDP-DNA WBC CR 212 amole/pg DNAb
Ovarian cancer patients (55) PR 193 amole/ljg DNA
NR 62 amole/Ig DNA
aSamples positive by radioimmunoassay/total samples.
bPeak levels: CR, complete response; PR, partial response; NR, no response to therapy.
Table 5. Detection of aromatic DNA adducts by 32P-postlabeling.
Source of exposure DNA analyzed Subjects Observations
Cigarette smoke Placenta Smokers (16/17) Adduct 1 1.4/108 N (P1)
2.0/106 N (ELISA)
Nonsmokers (3/14) Adduct 1
Cigarette smoke Bronchus, larynx Smokers (2) Total adducts 1/(1.7-2.9 x 107 N)
(0.10-0.18 fmole/lg DNA)
Adduct 1 8-14% of total
Betel chewing Oral mucosa Exposed (59) Adducts found in 30-95%
Tobacco chewing Levels 1/109 N-1110 7 N
Inverted smoking
Cigarette smoke Oral mucosa Smokers (11/11) Total adducts 0.1-210 amole/Mg DNA
Nonsmokers (2/8) Total adducts 0.4-1.7 amole/Ag DNA
Foundry workers WBC Exposed (10/10) Total adducts 0.2-11.6/108 N
Controls (5/10) 0.4/108 N
Wood smoke Placenta, WBC Exposed: Placenta (4) Total adducts 12/109 N
WBC (8) Not detected
Control: Placenta (5) 12/109 N
WBC (8) Not detected
actions with proteins ornucleic acidswasmeasured as an
index ofcarcinogen exposure. Lu at al. (9) determinedthe
daily excretion ofnitrosamino acids in Chinese population
groups residing in areas ofhigh orlow risk for cancer of
the esophagus. This study was designed to gain evidence
concerning a possible etiologic role for N-nitroso com-
pounds, some ofwhich are effective esophageal carcino-
gens in animals, as risk factors for man. The substantially
higher values observed in persons in the high risk area
indicate a higher level ofexposure to these carcinogens
duringthe studyperiod. A similar approach was usedby
Hoffman and Brunnemann (10) to define the potential of
inhaled cigarette smoke for endogenous N-nitrosation of
amines. The datarevealed not only the existence ofasub-
stantial background of endogenous nitrosation in non-
smoking controls, but also a significant increase in
smokers. Garland etal. (11)conducted an extensive inves-
tigation of individual and interindividual differences in
the excretion ofnitrosoproline in healthy volunteer sub-
jects, allbut two ofwhomwerenonsmokers. Asindicated
in Table 1, the average value for these subjects is very
close to that for the nonsmoking controls and residents
of the low-risk areas in the earlier studies. In each of
these studies, ingestion of ascorbic acid was shown to
lowerthe excretion rates, as expected. Thegeneral inter-
laboratory agreement withrespecttothevaluesreported
indicates the potential value ofthis measurement in de-
tecting exposure to nitrosating agents in the environ-
ment.
Assessment ofhuman exposure to aflatoxins through
measurement ofurinary excretion ofthemajor DNA ad-
duct has been reported in two studies. Groopman et al.
(12)usedthetechnique ofimmunoaffinitypurification cou-
pledwith HPLC detection to identifytheguanine adduct
ofaflaxtoxin B1 in the urine ofpersonsresidingin a com-
mune in Guangxi Province ofChina, where independent
evidence indicated that the dietary contentofthe carcino-
genwashigh. The analytical methodwasadequately sen-
sitive to detect the presence ofthe adduct in persons ex-
posed at high levels, and also to quantify the excretion
of aflatoxin Ml, a metabolite, as well as unmetabolized
carcinogen. Aflatoxin exposure was also measuredby uri-
nary excretion ofthe guanine adduct in populations liv-
ingin areas with differentlivercancerincidence in Kenya
by Autrup et al. (13). The presence ofthe adduct was de-
tected by HPLC used in combination with synchronous
scanningfluorescence spectrophotometry, anditwas de-
tected in 12% ofa large series (983) ofsamples collected
over a period ofyears in different areas ofthe country.
Both analytical methods require sophisticated analytical
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instrumentation and are not yet applicable for routine
monitoring.
Two additional approaches based on analysis ofurinary
components arebeingdeveloped as potentialmonitors for
exposure to genotoxic exposures. Shuker et al. (14) have
explored the measurement of3-methyl adenine in urine
as an indicator ofexposure to methylating agents. As in-
dicated in Table 1, they have developed aGC-MS method
using single ion monitoring capable of detecting the
methylated baseinnominallyunexposed individuals. Fur-
ther validation ofthe method will be required to deter-
mine its usefulness as an exposure monitor. Cathcart et
al. (15)used an HPLC assay fordetermininglevels offree
thymine glycol and thymidine glycol inurine, as a nonin-
vasive assay foroxidative DNAdamage, since these com-
pounds areproducts ofDNA damage caused by ionizing
radiation andotheroxidative mutagens. While theywere
able to determine excretion rates forboth compounds in
healthy individuals, the method is very labor intensive
and time consuming, and in its present form has found
only limited application.
Hemoglobin Adducts
A summary ofrepresentative dataonmeasurements of
hemoglobin adducts derived from exposure to carcino-
gens is presented in Table 2. Most of the work done to
date has concerned the measurement ofN-3-(2-hydroxy-
ethyl)histidine (HEH) orhydroxyethylvaline (HV)as mo-
nitors ofexposure to ethylene oxide. This methodology,
in which the alkylated derivative was measured by GC-
MS, was developed by Ehrenberg and his colleagues, and
was used in the study ofoccupationally exposedworkers
(16). Average data shown inTable 2forexposed subjects
and unexposed controls indicate the sensitivity of the
method for detecting exposure. Other findings in this
study indicated the general agreement of the data ob-
tained in man with those predicted from earlier studies
in the mouse and also demonstrated the superiority ofthe
method forproviding a cumulative measure ofexposure
as compared to point monitoring of air levels.
The same methodology was subsequently applied by
Van Sittert et al. (17) in a study ofworkers in an ethy-
lene oxide manufacturingplant, in which cytogenetic and
immunologic endpoints were made simultaneously inthe
same individuals. These investigatorsreported a substan-
tially higherbackground ofHEH in their control subjects
and reported no significant difference between exposed
and unexposed persons. Farmer et al. (18) compared
levels of HEH, as determined by GC-MS on protein
hydrolysates inwhichthe adductwas concentratedbyion
exchange chromatography, withlevels ofHV determined
by GC-MS analysis of hemoglobin subjected to Edman
degradation before analysis. They found that the two
methods ofanalysis gave consistent results, especially at
high levels, and also that higher levels of background
alkylation (ofunknown origin) were obtained in measure-
ments ofHEH than with HV, suggesting that the latter
assay would show greater sensitivity in monitoring ex-
posure to ethylene oxide. Thismethod was subsequently
applied in a study ofcigarette smokers and nonsmokers
(19). The results demonstrated an elevation ofHV levels
in smokers that was quantitatively compatible with mea-
suredlevels ofethylene in the smoke to whichtheywere
exposed.
Bryant et al. (20)have developed amethodforthe anal-
ysis of4-aminobiphenyl covalently bound as the sulfinic
acid amide to the 93-beta cysteine ofhuman hemoglobin.
The method involves hydrolysis of the hemoglobin fol-
lowed by GC-MS determination ofthe parent amine af-
ter derivatization. Application ofthe method to smokers
and nonsmokers revealed consistently elevated levels in
smokers and also a detectable background ofthe adduct
in nonsmokers ofundetennined origin. Collectively, these
results indicate the applicability ofanalysis ofhemoglo-
bin adducts asmonitors ofexposure to carcinogens ofdif-
ferent structural types and mode of action.
Detection of BPDE Adducts in DNA by
Immunoassay or Chemical Analysis
Several studies have been conducted to date thatwere
designed to determine exposure to the ubiquitous poly-
cyclic aromatic hydrocarbon benzo[a]pyrene (BaP)
through the detection ofderivatives covalently bound to
DNA. Immunoassays andphysicochemical methods have
been applied to detect derivatives formed through the
major intermediate in the activation pathway, the
benzo[alpyrene-7,8-diol-9,10-epoxide (BPDE). Immunoas-
says have been applied intwo modes, enzyme-linked im-
munosorbent assay, (ELISA) and ultrasensitive enzyme
radioimmunoassay (USERIA), both employingpolyclonal
antisera that recognize BPDE-DNA adducts, with vari-
ous levels of cross-reactivity with structurally related
congeners. In an early pilot study in humans, Perera et
al. (21) demonstrated that the ELISA assay was suffi-
ciently sensitive to detectadductsin the DNAextracted
fromlungtumors aswell asfrom nontumortissue inlung
cancerpatients, butthe small numberofsubjects studied
precluded conclusions concerning exposure history.
Shamsuddin et al. (22)employed ELISA and USERIA
assays to investigate the levels of BPDE-DNA adducts
in the white blood cells (WBC) of roofers and foundry
workers, inview oftheirexposure to high levels ofBaP.
Adducts were detected in a significant proportion ofex-
posed individuals and also in2/9 control subjects, both of
whom were cigarette smokers. The technique of syn-
chronous scanning fluorimetric spectrophotometry
(SSFS) was applied in the analysis of DNA ofWBC col-
lected from workers in an aluminum plant for the pres-
ence ofBPDE-DNA adducts (23). The limit ofdetection
of this method as applied is about one adduct in 107
nucleotides. One sample ofWBC DNAfromthe series of
30 exposed subjects showedthe presence ofa detectable
level of BPDE.
Harris et al. (24) analyzed the DNA of WBC of coke
ovenworkersby USERIAandbySSFSto determine the
frequency andlevels ofBPDE adducts as markers ofex-
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posure, asthese workers are knowntobe exposedto high
levels ofBaP and are also at anelevatedriskoflung can-
cer. Approximately two-thirds ofthe workers had detect-
able levels ofBPDE-DNA adducts as determined by im-
munoassay, and an even larger proportion showed
spectral evidence ofthe presence ofBPDE bythe SSFS
assay. Antibodies tothe DNAadductswere also detected
in the serum of27% ofthe workers. Coke oven workers
were also the subjects of a study by Haugen et al. (25),
who sought to evaluate the genotoxic effects oftheir oc-
cupational exposures through a study ofBPDE-DNAad-
ducts with simultaneous measurements ofurinary excre-
tion of PAH metabolites and air monitoring. As in the
earlier study, DNAadducts weremeasuredby USERIA
and SSFS, andthe serawere examined forthepresence
ofanti-DNA adduct antibodies. The results ofthe study
were in close agreement with those obtained earlier by
Harris et al. (24) in all respects. Perera et al. (26) have re-
cently applied ELISAinthe study ofPAH adducts inthe
DNA of WBC collected from Finnish foundry workers
classified ashavinghigh, mediumorlowexposure, aswell
as unexposed control subjects. Mean levels of DNA ad-
ducts increased with exposure, and there was a highly
significant difference between the control andpooled ex-
posure group means.
Immunoassay techniques have alsobeenused to detect
adducts of DNA-damaging agents other than BPDE.
Radioimmunoassay of06-methyldeoxyguanine was per-
formed by Wild et al. (27) on human esophageal and
cardiac stomach mucosal DNA from tissue samples ob-
tained during surgery in Linxian County, China, an area
ofhighriskforbothesophageal andstomach cancer. Simi-
lar analyses were conducted on samples collecteci from
hospitals in Europe. Withthismethodology, 06-MeGwas
detected in abouttwo-thirdofsamplesfromthehigh risk
area, as compared to 5/12 from the control area. Adduct
levels were also higher in samples from people living in
the high risk areas. DNA adducts induced by the an-
ticancer drug cis-diamminechloroplatinum (II) were de-
tected in the WBC of cancer patients treated with the
drug through application of ELISA methodology (28).
The immunoassay procedure used four antisera capable
of detecting different adducts, including intrastrand
cross-links on pGpG sequences (which proved to be the
major adduct); intrastrand cross-links on pApG se-
quences; inter- or intrastrand cross-links on twoguanines
separated by one or more bases; or monofunctional ad-
ducts bound to guanine. Results indicated that the sus-
ceptibility ofWBC to adduct formation can show strong
individually determined differences.
Reed et al. (29) also used ELISAmethodology to study
adducts derived from cis-platinum in WBC of ovarian
cancer patients being treated with the drug. Values for
median adductlevels weregroupedbycomplete response
(CR), partial response (PR), and no response (NR), and
statistical analysis ofthe data showed that higher level
ofadduct formation correlated with clinical responsive-
ness to the drug.
These datashowthatadductsformedin DNAofacces-
sible cells ofpeople exposed to DNAdamaging agents of
avariety oftypes canbe detected, and in many instances
quantified, by currently available immunological and/or
chemical methods. Application ofthese methodologies in
well-designed longitudinal studies in manwillperrnitfur-
ther evaluations oftheirvalidity and limitations in actual
use.
Detection ofAromatic DNA Adducts by
32P-Postlabeling
The postlabeling procedure developed by Randerath
and his collaborators has been extensively applied to
studies of DNA adduct formation in a variety of ex-
perimental systems, and the ability ofthe methodology
to detectadducts ofalarge numberofcarcinogens(about
50) has been reported. The procedure has recently been
extended to studies in humans, with results that can be
summarized as follows. Everson et al. (30) investigated
the presence of DNA adducts in human term placentas
by both ELISA and by the 32P-postlabeling assay. The
immunoassay revealed a small but insignificant increase
in BPDE adduct levels in placentas from smokers com-
pared to nonsmokers. However, the postlabeling assay
detected anumber ofadduct types, the major one being
strongly related to maternal smoking duringpregnancy.
Subsequently, Randerath et al. (31) compared adduct
levels in humanbronchus andlarynxfrom smokerswith
those produced in mouse skin treated with cigarette tar.
The human tissues were found to contain detectable
levels ofadducts, one ofwhich(designated adduct 1) was
identical to a major and persistent adduct formed in
mouse skin. Dunn and Stich(32)usedthepostlabeling as-
say to investigate DNA adducts in exfoliated mucosal
cells collected from the oral cavityofthreegroups at high
riskfororal cancer. Five chromatographically distinct ad-
ducts were found in both the high riskgroups and nons-
mokingcontrols. Individual adducts were detectedin 30
to 90% ofthe samples, and no adductswerefound inhigh
risk groups that did not also appear in control groups.
Thus, although the method was successful in detecting
adducts derived from unknown sources, it did not
differentiate between exposed and nonexposed popula-
tions.
Usingthe same approach, Chacko and Gupta (33) ana-
lyzed the DNA from oral mucosal cells of cigarette
smokers and nonsmokers to determine whether smoking-
related adducts couldbeidentified. Two chromatographi-
cally distinctadducts ofunknownidentitywerefound in
smokersbutnot innonsmokers. Inaddition, the levels of
thesemajorandseveral minoradductswere substantially
higherin smokers. Phillips etal. (34)analyzed DNAfrom
normal human bone marrow mononuclear and non-
mononuclear cells for the presence ofaromatic adducts.
Tenoutof10individuals showedthepresence ofadducts,
which were not present in fetal bone marrow, but were
present at lower levels in the DNA ofperipheral WBC.
Their datasuggested thatthe adducts resultedfrom en-
vironmental exposure to unidentified genotoxic agents.
Phillips et al. (35) also employed the postlabeling assay
toanalyzeWBC DNAfromfoundry workersforthepres-
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ence ofadducts that might reflect differing levels ofex-
posure to BaP. Adducts were found in 10/10 workers at
levels detectable by the analytical method, but none of
these had the chromatographic properties characteristic
ofadducts derived from BaP. Adducts were also identi-
fiedin nonexposed control subjects. The results indicated
significant interindividual differences in DNA binding
among people receiving similar levels of exposure.
Reddy et al. (36)investigatedWBC andplacental DNA
for the possible presence of adducts derived from ex-
posure ofpregnant women to residential wood combus-
tion smoke. Detectable levels of unidentified adducts
were found in all placentas of exposed and nonexposed
women; none of the nine adducts found was present in
WBC DNA of any of the subjects. The results suggest
thatresidential woodcombustion smoke did notelicit aro-
matic DNAadducts at detectable levelsbutthatplacen-
tal DNA contained detectable levels of adducts of un-
known identity or origin. Collectively, these results
demonstrate the capability ofthepostlabelingmethodto
detect DNA damage arising from a variety of environ-
mental exposures. However, additional experience with
its applications in human studies will be required to es-
tablishfully thepertinent analytical characteristics ofthe
method.
DNA Adducts and Hemoglobin
Adducts as Measures of Exposure
and Susceptibility
The information summarized previously provides valu-
able evidence concerning some features of currently
available methodologies for detecting and quantifying
covalent adducts to DNAandhemoglobinin humanmate-
rial. The data show that detecting exposure to carcino-
gens of a variety of chemical types is feasible using
methods currently available orbeing developed. Substan-
tial additional technologicalrefinement andvalidationwill
be required before any of the current methods will be
routinely applicable in large-scale epidemiologic studies.
However, it seemslikely thatmanyofthemwill eventu-
ally come into broader application. In interpreting the
data generated by their application, it is important to
take into account all pertinentinformation concerningthe
parameters being measured. Some of the important
points in this context can be summarized as follows.
Concerning the use ofDNA adduct levels as measure
ofexposure and susceptibility, virtually all ofthe avail-
able evidence comes from experimental systems, espe-
cially experiments in which adduct formation in
carcinogen-treated animals were studiedin relation to tu-
mor formation in response to the treatment. Most car-
cinogens have been shown to form complex spectra of
DNA adducts, and qualitatively similar adduct profiles
can be formed in sensitive and resistant spe-
cies/strains/tissues. Adduct persistence may ormay not
be related to susceptibility and/or target tissue specific-
ity. In target tissues, maximum total adduct levels
usually reflect carcinogen potency and dose, and maxi-
mumtotal adductlevels are linearlyrelatedto dose over
awide range. Manyfactorshavebeenidentifiedthat can
affect the levels of DNA adducts observed in cells of
treated animals at any given time. The exposure-
samplinginterval canmarkedlyaffectobservedlevels, as
determinedbythepharmacokineticproperties ofcarcino-
gens ofspecific chemical types. An important component
ofthis process is the capability formetabolic activation,
which can be affected by a variety ofgenetic as well as
environmental factors (e.g., inducers or inhibitors). Ex-
posure toprotective agents such as antioxidants orother
dietary ingredients can also exertmarked effects. DNA
repair capacity, as determinedbygeneticfactors, as well
asIdnetics(e.g., saturability), ormodulatingfactors isalso
an important determinant of adduct stability. Collec-
tively, these factors indicate the complexity ofthe prob-
lem ofmeaningful interpretation of DNA adduct levels
as quantitative measures of exposure.
In relation to the use ofDNA adduct levels as indica-
tors oflong-ternrisk, the situationisfurther complicated
by additionalfactors. Generally, the target tissue at risk
to a given genotoxic exposure is unknown, and reliance
must be placed upon measurements of adduct levels in
surrogate cells such asperipheral white blood cells. The
validity ofthe DNA analyzedfor target cell DNA is dif-
ficult to assess. Extrapolation of DNA adduct levels as
indicators ofcancerrisknecessarily entailssimplifyingas-
sumptions about themultistage nature ofthe cancerpro-
cess, whichcannotbeevaluatedwithcurrentinformation.
In addition, point measurements of DNA adduct levels
may or may not provide evidence ofmultiple and varia-
ble exposures.
Protein adducts have no putative mechanistic role in
carcinogenesis and are primarily regarded only as mea-
sures ofexposure. Evidence from experimental animals
andfromhuman studies supportingtheinterpretation of
protein adduct levels as exposure monitors can be sum-
marized asfollows. Measurement ofhemoglobin adducts
hascertain obvious technicaladvantages, inasmuchasthe
protein can readily be obtained in abundant quantities.
Sensitive and specific methods have been developed for
two classes ofcarcinogens, andadditional ones are inthe
process ofdevelopment. Carcinogens ofdiverse chemical
structures have been shown to bind to hemoglobin in
vivo. Adducts are stable over the erythrocyte lifespan,
thereby giving an integrated measure of multiple ex-
posures over a substantial time period. Levels ofhemo-
globin adducts have been shown to be linearly related to
dosefor atleast sevencarcinogens ofdifferenttypes. Im-
portantly, hemoglobin adduct levels have been shown to
be related, within afactor oftwo, to DNA adduct levels
in target tissues for three agents: ethylene oxide,
trans-4-dimethylaminostilbene, and 2-;cetylaminofluo-
rene. Hemoglobin adducts therefore provide very useful
complementary datato DNAadductlevels as dosimeters
of carcinogen exposure.
Thisinformation, derivedfrom applications ofcurrent
methodologies for detecting and quantifying levels of
DNA and hemoglobin adducts in human samples indi-
cates that adequate levels of sensitivity have been at-
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tained for several classes of DNA damaging agents to
makepossible the detection ofadductsresultingfromam-
bient levels ofexposure. Specificity for the detection of
compounds ofknown structure is also a common feature
ofmost ofthe methods, and some are suited to detect to-
tal DNA damage frommultiple sources. Withrespect to
practicability, certain of the methods (e.g., immunoas-
says) are applicable tolargenumbers ofsamples, whereas
others (e.g., postlabeling, thymine glycol analysis) are
technically more complex andtime consuming. Validation
will be required to avoid systematic errors in measure-
ment before the methods are applicable to large scale
epidemiological studies. Methodological attributes such
as accuracy, reproducibility (intra- andinterlaboratory),
and applicability to stored samples will need to be deter-
mined by appropriately designed collaborative studies
among qualified laboratories. Additional factors such as
variations ofobserved values due to age, sex, race, etc.,
aswell as effects ofpossible interferingfactors(e.g., diet,
smoking, alcohol, etc.) will require definition through
properly designedhuman studies oflimited scopeinorder
to validate the approach for epidemiological surveys.
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